 Home >

Medical News

Home



Latest Medical News

Guiding opinions on further promoting the development of the integration of medical and nursing care

 Time of Update: 2022-10-06

All relevant departments in all localities should adhere to the guidance of Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era, conscientiously implement the decision-making and deployment of the Party Central Committee and the State Council, further improve policies and measures, focus on solving difficult problems and blockages, promote the development of medical and nursing care, and continuously meet the needs of health and old-age services for the elderly.
The CCR8-targeting monoclonal antibody CM369 jointly developed by Nuocheng Jianhua and Connoya has been approved for clinical use

 Time of Update: 2022-10-06

BEIJING, Aug. 24, 2022 /PRNewswire/ -- Nuocheng Jianhua and Connoya jointly announced today that they have received the "Notice of Drug Clinical Trial Approval" approved and issued by the State Drug Administration The CCR8-targeting monoclonal antibody CM369 developed by Nuojiancheng has carried out clinical trials in advanced solid tumors .
Keji Pharmaceutical Announces 2022 Interim Results: Continue to Promote CAR-T Technology Innovation and Product Pipeline

 Time of Update: 2022-10-06

SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- Keji Pharmaceuticals, an innovative CAR-T cell therapy company primarily focused on the treatment of hematological malignancies and solid tumors, has announced
Dekang Tongzhi Rhinitis ® Granules won the "2021~2022 Chinese Family Regular Medicine Listed Brand"

 Time of Update: 2022-10-03

Recently, the "2021-2022 China Family Shelf Medicine Listed Brands", which is loved by the public, authoritative, professional, convenient and practical, was officially released to the public. The eve
Aiming at the NASH drug market of more than 30 billion yuan, nearly 20 domestic pharmaceutical companies are actively deployed!

 Time of Update: 2022-10-03

Recently, the American biotechnology company Akaro released positive data on its new NASH drug Efruxifermin in the Phase IIb HARMONY study, which has attracted great attention from the industry, and the drug has once again pushed NASH, the field of disease treatment research and development.
In order to cope with the challenges of transformation or upgrading, M&A activities of pharmaceutical companies are becoming increasingly enthusiastic

 Time of Update: 2022-10-03

In addition, Huadong Pharmaceutical also announced on August 9 that it will invest a total of no more than 396 million yuan to acquire 60% of the equity of Huaren Technology.
Is there still an opportunity in the pharmaceutical sector in the fourth quarter? The industry is optimistic about these subdivision tracks

 Time of Update: 2022-10-03

The industry believes that after the valuation digestion of the CXO sector in the past two years or so, the overall valuation has returned to a more reasonable range, and the low allocation value of the plate is highlighted in the long run.
Do a good job in "prevention", "control" and "treatment" - in the past ten years, China's endemic disease prevention and control has achieved historic results

 Time of Update: 2022-10-03

In the past ten years, no new endemic cretinosis patients have been found in China, iodine deficiency disease has reached a continuous elimination state, there are basically no new cases of osteoarthritis in China, and the number of soil-derived nematodes and foodborne parasitic infections has decreased significantly.
Innovative drug companies and Chinese medicine companies have a large number of general managers leaving!

 Time of Update: 2022-10-03

Since the beginning of this year, the senior management of pharmaceutical companies has changed, and a large number of senior executives such as general managers of pharmaceutical companies have resigned for personal reasons, work adjustments and other reasons, and it has been particularly frequent since the second half of the year.
Innovation in traditional Chinese medicine continues to accelerate, and pharmaceutical companies are using digital technology to promote industrial upgrading

 Time of Update: 2022-10-03

Chinese medicine pharmaceutical companies are using digital technology to promote industrial upgrading (Source: Pharmaceutical Network) It is understood that in recent years, benefiting from the support of a series of favorable policies, the strategic position of traditional Chinese medicine is constantly improving.

Medical World News

New crown oral drugs and a variety of rare disease drugs passed the 2022 medical insurance catalogue adjustment review

 Time of Update: 2022-10-02

From September 6 to 12, 2022, our bureau announced to the public the "List of Declared Drugs Approved by the Preliminary Form Examination of the Adjustment of the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue in 2022".
The Ministry of Industry and Information Technology will carry out the action of strengthening the chain of the pharmaceutical industry chain

 Time of Update: 2022-10-02

Zhou Jian, deputy director of the Department of Consumer Goods Industry of the Ministry of Industry and Information Technology, said on the 14th that it will carry out the action of strengthening the chain of the pharmaceutical industry chain, focus on weak links, support upstream and downstream enterprises in the industrial chain to carry out collaborative research, and continue to enhance key core competitiveness.
Domestic pharmaceutical innovation is active Experts: Accelerate the speed of domestic innovative drugs to go to sea

 Time of Update: 2022-10-02

(End) Disease tumor medicine and health enterprises Professor Jiang Jie, dean of the Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical and Medical Device Real-World Research Institute of Jinan University, recently said through video at the 2021 China Biomedical Enterprises Top 100 Innovative Strength Series List Conference that domestic pharmaceutical innovation is active, and favorable and negative policies guide and force enterprises to innovate.
Notice of the State Food and Drug Administration on 17 batches of drugs that do not meet the regulations

 Time of Update: 2022-10-02

, Ltd. did not meet the regulations, and the items that did not meet the requirements were prohibited pesticide residues 。 After inspection by Gansu Provincial Drug Inspection and Research Institute, 1 batch of madder marked as produced by Sichuan Yuanshang Herb Chinese Medicine Tablet Co.
Hainan: Repeal the "Implementation Measures for Rewarded Reporting on Food and Drug Safety in Hainan Province"

 Time of Update: 2022-10-02

Medicines According to the news on the website of the People's Government of Hainan Province on the 18th, the General Office of the People's Government of Hainan Province recently issued a notice on the abolition of the "Implementation Measures for the Reward for Food and Drug Safety Reporting in Hainan Province".
Raw materials such as dogwood are rising, and the cost of Yibai Pharmaceutical is increasing!

 Time of Update: 2022-10-02

Ginseng, the new production continues, this year's production area rains more, but the market supply of goods, the recent merchants small batch procurement, the source of goods moving around, the market is running stably, the price of 80 raw drying goods is between 255-260 yuan, and the price of raw sunning 45 is between 320-330 yuan.
Shanghai to build a high-quality medical service system: "top of the sky, strong waist, standing"

 Time of Update: 2022-10-01

At the press conference of the special series of party committees held by the Shanghai Municipal Government on the 22nd, Wu Jinglei, deputy secretary and director of the party group of the Shanghai M
The State Food and Drug Administration released the conversion of pain relief capsules into over-the-counter drugs

 Time of Update: 2022-10-01

Model instructions for over-the-counter drugs State Food and Drug Administration September 16, 2022 drugsAdministration of Drug Registrationenterprisesover-the-counter drugs serial number name of article Specifications (composition) classify remark 1 Pain Relief Capsules 0.
Information on medical device licensing in each province (as of August 31, 2022)

 Time of Update: 2022-10-01

In order to further meet the needs of enterprises and the public to inquire about medical device regulatory information and strengthen social supervision and social co-governance, the State Food and
Can this summer's drought in Gansu help the price of astragalus break through?

 Time of Update: 2022-10-01

In the Gansu traditional Chinese medicine "troika" of angelica, ginseng, astragalus, astragalus price fluctuations are the most "gentle", are the annual use of more than 40,000 tons of varieties, why

Medical Research Articles

TUV Rheinland issued MDR certificates for Huawei's ECG analysis prompt software and blood pressure watch

 Time of Update: 2022-10-03

62em; font-family:"Arial"; color:black; margin:0in; } Shenzhen, September 16, 2022 /PRNewswire/ -- Recently, TUV Rheinland, an international independent third-party testing, inspection and certification body, has issued an ECG Alert Software (ECG App) and a Huawei Blood Blood Pressure Monitor based on the European Union Medical Device Regulation (EU) to Huawei Terminal Co.
The 3rd Huizhi "Painless Far" Pain Summit Forum was held

 Time of Update: 2022-10-03

Professor Pei Fuxing, tenured professor of West China Hospital of Sichuan University and deputy head of the orthopedic expert group of the Accelerated Rehabilitation Surgery (ERAS) Expert Committee of the National Health Commission, said: "Osteoarthritis is showing a continuous growth and rejuvenation trend in China, of which about 1/3 of the patients are young and middle-aged, which has become a serious health problem facing the public and society.
Information on medical device licensing in each province (as of August 31, 2022)

 Time of Update: 2022-10-03

In order to further meet the needs of enterprises and the public to inquire about medical device regulatory information and strengthen social supervision and social co-governance, the State Food and
Still worried about the poor quality of water produced by purification water equipment? Let's take a look at these points

 Time of Update: 2022-10-03

, and if the water inlet requirements of the subsequent process are still not met, the measures for removing organic matter such as activated carbon filtration can be added.
PharmaLink 2022 The 5th Small Molecule Innovative Drug Development and Cooperation Conference, see you in Shanghai in October!

 Time of Update: 2022-10-03

Embracing opportunities, seeking development and promoting cooperation, the "PharmaLink 2022 5th Small Molecule Innovative Drug Development and Cooperation Conference" hosted by Courtyard Medical will
Long awaited! MERFISH super-resolution spatial transcriptomics technology service is finally here!

 Time of Update: 2022-10-02

Realize the true sense of in situ single-cell spatial genome analysis, visualize the expression and localization of genes, and promote the research of genomics into the next generation!Advantages of MERFISH spatial transcriptome technology1.
Thermo Scientific announces investment in Guangzhou to build a Guangdong-Hong Kong-Macao Greater Bay Area base

 Time of Update: 2022-10-02

After the completion of the Guangdong-Hong Kong-Macao Greater Bay Area Base, it will make full use of Thermo Fisher's cutting-edge technology advantages in the field of scientific services to produce high-value-added products including high-end laboratory equipment, analytical instruments and laboratory consumables.
The research progress of BCMA CAR-T product CT053 North America Phase 2 of Keji Pharmaceutical was presented at the 7th CAR-TCR Annual Summit

 Time of Update: 2022-10-02

HK), an innovative CAR-T cell therapy company focused primarily on the treatment of hematologic malignancies and solid tumors, announced that at the 7th annual CAR-TCR Summit in Boston, Massachusetts, the company orally presented Zevor-cel (product number: CT053) (an autologous CAR-T candidate for BCMA) North America2 Phase clinical trials.
Kexing Pharmaceutical Changlekang was awarded the "2021~2022 Chinese Family Shelf Medicine Listed Brand"

 Time of Update: 2022-10-02

/* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prnews
Merck invested €29 million to open a biosafety testing laboratory in Shanghai

 Time of Update: 2022-10-02

/* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prnews

Medical Science News

The multinational pharmaceutical company has approved the listing of a number of new drugs in China

 Time of Update: 2022-10-03

For example, recently, the website of the Drug Evaluation Center (CDE) of the State Food and Drug Administration showed that the application for the listing of Pfizer JAK3 inhibitor litecotinib capsules was accepted for the treatment of adolescents aged 12 and over and adults alopecia areata.
This pharmaceutical machine company has been investigated by the institution, and the company's products have a strong competitive advantage

 Time of Update: 2022-10-02

According to reports, the main business of Tailin Biology is the research and development, manufacturing and sales of pharmaceutical equipment such as microbial detection and control technology system products and organic matter analysis instruments.
This pharmaceutical company has blossomed in the field of new oncology drugs, and another new drug has been approved clinically!

 Time of Update: 2022-10-02

It is worth noting that in addition to SHR-A2102 injection, Hengrui Pharmaceutical recently issued an announcement that it received the "Drug Clinical Trial Approval Notice" approved by the State Food and Drug Administration on HRS-6209 capsules, and will carry out clinical trials in the near future.
Today, another new pharmaceutical stock will be listed on the GEM!

 Time of Update: 2022-10-01

It is worth mentioning that in addition to the external lotion of gynecology, Enwei Pharmaceutical has not disconnected the dosage forms such as ointments, suppositories, effervescent tablets and disinfection products such as bacteriostatic lotion, and intends to develop gynecological internal medicine series products in independent research and development, joint research and development, purchase of varieties and other ways, and constantly maintain and further enhance the company's advantages in the field of domestic gynecological products.
In the first half of the year, domestic pharmaceutical companies with R&D investment of more than 1 billion yuan have a variety of potential first-in-class

 Time of Update: 2022-10-01

According to reports, JS004 is the world's first recombinant humanized anti-BTLA monoclonal antibody specifically targeting B and T lymphocyte attenuation factor (BTLA) that has entered the clinical development stage of the company's independent research and development.
In order to be more streamlined, Novartis plans to lay off thousands more people and close some factories

 Time of Update: 2022-10-01

Since the beginning of this year, Novartis, a leading multinational pharmaceutical company, has made continuous moves, first announcing the adjustment of the company's global business framework, planning to lay off 8,000 employees, and then integrating the two business units of pharmaceuticals and oncology into one innovative drug department, while merging the technology operations, customers and technical departments.
In the 100 billion market, this pharmaceutical company with a large number of new drugs is accelerating the grabbing of food

 Time of Update: 2022-09-30

In fact, in recent years, Yangtze River Pharmaceutical and its subsidiaries are still increasing the research and development of nervous system drugs, in addition to the advantages of pain relief, mental stability, local anesthesia, but also expanded to other subcategories.
Two chemical drugs have been approved one after another! The landing of pipeline products of the pharmaceutical company is gradually being cashed in

 Time of Update: 2022-09-14

On September 6, Tasly announced that jiangsu Diyi, a wholly-owned subsidiary of the company, recently received the "Drug Registration Certificate" approved and issued by the State Drug Administration on bortezomib for injection.
In order to enhance competitiveness, this traditional Chinese medicine formula granule company has increased capital and shares!

 Time of Update: 2022-09-09

For example, on June 29 this year, Yibai Pharmaceutical announced that, by consensus, the company plans to jointly increase the capital of Yibai Formula Granules, a wholly-owned subsidiary of the company, with the Guizhou Agricultural Development Fund to invest in the construction of the company's entire industry chain project of traditional Chinese medicine formula granules .
This traditional Chinese medicine company issued 19 announcements in one day, related to the semi-annual report, the departure of executives, etc.

 Time of Update: 2022-09-09

1576 million, and the financing balance decreased ; According to information from the Shenzhen Stock Exchange, on August 26, *ST Bikang issued 19 announcements in succession, which were related to the interim report performance and the resignation of executives .

Medicines Company News

Shanghai Municipal Public Health Clinical Center completed the clinical study of PD-L1 antibody ASC22 (envorizumab) combined with sidabenamide for functional cure of HIV infection

 Time of Update: 2022-10-03

The study (clinical trial registration number: NCT05129189) aimed to evaluate the efficacy of ASC22 (envorizumab) plus cedabenamide in HIV-infected people on infected incubation cell virus reservoirs. The study (clinical trial registration number: NCT05129189) aimed to evaluate the efficacy of ASC22 (envorizumab) plus cedabenamide in HIV-infected people on infected incubation cell virus reservoirs.
Corning Jerry HER2 Dual Anti-Conjugated Drug (KN026-ADC) JSKN003 completed the first patient administration in a phase I clinical study in Australia

 Time of Update: 2022-10-02

HK) announced that the company's self-developed HER2 bispecific antibody conjugated drug (KN026-ADC, R&D code: JSKN003) in Australia to treat advanced solid tumors Phase I clinical research completed the first patient administration.
Deservedly, the honor was on the list - Kexing Pharmaceutical Changle Kang was awarded the "2021~2022 Chinese Family"

 Time of Update: 2022-10-02

(hereinafter referred to as "Kexing Pharmaceutical", stock code: 688136) were honored to be on the list with its excellent product quality and winning reputation!After layers of selection and fierce competition, on September 19, the list of "2021-2022 China Family Standing Health Products Listed Brands" was announced, and the probiotic products Changlekang (Clostridium butyric acid bifieria) of Kexing Biopharmaceutical Co.
The National Institute for Health and Clinical Excellence recommends Baiyueze? (Zebutinib) is used to treat patients with Fahrenheit macroglobulinemia who have previously received at least one treatment

 Time of Update: 2022-10-02

NICE's positive recommendation to Beaux-Benz ® will help patients in England and Wales who meet the treatment criteria have this important new treatment option that delivers better outcomes than current standard treatments.
Shanghai Pharmaceutical strengthens innovation and research and development to promote the high-quality development of the biomedical industry

 Time of Update: 2022-09-30

Recently, when Shanghai Pharmaceutical was surveyed by investors, it said that the company's clinical applications have been accepted and entered the clinical research stage of the new drug pipeline
Good news! Shandong Dingxin was elected as a director unit of the Professional Committee of Chinese Herbal Medicine Processing Equipment

 Time of Update: 2022-09-30

As a professional manufacturer in the field of shredding equipment, Shandong Dingxin has always focused on the innovation and breakthrough of shredding technology, continuously improving the crushing efficiency and crushing capacity of pulverizer equipment, and providing strong equipment and technical support for traditional Chinese medicine and other industries.
600 million yuan! The leading API company has greatly expanded its production capacity

 Time of Update: 2022-09-30

The company intends to use its own funds to invest 600 million yuan in a new API production base project in Zhongxiang City, Hubei Province. The company intends to use its own funds to invest 600 million yuan in a new API production base project in Zhongxiang City, Hubei Province.
Innovent Biologics PD-1/IL-2 bispecific antibody fusion protein IBI363 completed the first clinical patient administration in Australia

 Time of Update: 2022-09-24

” Cinda Biopharmaceutical Group (HKEx Stock Code: 01801), a biopharmaceutical company dedicated to the research and development, production and sales of innovative drugs in the field of oncology, self-immunity, metabolism, ophthalmology and other major diseases, Today announced the completion of its self-developed recombinant anti-programmed death receptor 1 (PD-1) antibody fusion interleukin 2 (IL-2) bispecific molecule (R&D code: IBI363) in a Phase I clinical trial in Australia for the treatment of advanced solid tumors or lymphomas.
BIOSET has entered into a collaboration with Bonn Biotech on the development of cell therapy drugs based on TCR-like antibodies

 Time of Update: 2022-09-21

On September 8, 2022, BIOSAITU (Beijing) Pharmaceutical Technology Co. , Ltd. (hereinafter referred to as "BIOSAITU", stock code: 02315. HK) announced that it has entered into a cooperation agreement
Sino-Cheng Jianhua announced the completion of the first patient administration in China in the Tafasitamab combined with lenalidomide for relapse/refractory DLBCL Phase II registered clinical trials

 Time of Update: 2022-09-21

Sino-Cheng Jianhua (HKEx: 09969) today announced that tafasitamab (Minjuvi®) in combination with lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) adult patients who are not suitable for autologous stem cell transplantation (ASCT) has completed phase II registered clinical trial (registration number: CTR20221519) in China.

Hot Products

Factory Hot Sale Raw Material CAS 19608-29-8 99.9% White powder 99% AM

CAS No.: 19608-29-8

Chemical Grade

$10-12/KG FOB

Hot Selling Ketoclomazone 2- (2-Chlorophenyl) -2-Nitrocyclohexanone 99.9% White to slightly yellow powder 2079878-75-2 99% AM

CAS No.: 2079878-75-2

Chemical Grade

$10-12/KG FOB

2-iodo-1-p-tolylpropan-1-one 99% 236117-38-7 99% AM

CAS No.: 236117-38-7

Chemical Grade

$10-12/KG FOB

Hot Tags

new drug approvals(72)

company(60)

new antidepressant drug(58)

pink new drug(57)

new drug pink(55)

new drugs market(54)

Hot Posts

Trending Keywords

Chemical Exhibitions

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.